Table 1.

Patient profiles, tumor characteristics, and treatment procedures in the patient groups treated with miriplatin and epirubicin in the targeted chemoembolization of hepatocellular carcinoma

Parameters	Chemotherapeutic agent		P value
	Miriplatin	Epirubicin
Sex (male/female)	30/17	43/21	0.839
Mean age (years)	70.7 (35–88)	70.1 (48–81)	0.928
Hepatitis (B/C/NBNC)	7/30/10	10/48/6	0.233
Child–Pugh class (A/B)	33/14	46/18	1.000
Clinical stage (I/II/III/IV)	11/32/18/5	16/45/16/2	0.110
Previous treatment (primary/recurrence)	25/22	40/24	0.337
Mean tumor size (mm)	17.6 (6–37)	17.6 (7–46)	0.999
Median AFP level (ng/mL)	19 (4–2098)	12 (3–6539)	0.743
Median DCP level (mAU/mL)	92 (6–1810)	93 (5–4760)	0.315
Chemoembolized area (segmental/subsegmental/distal)	20/28/8	20/36/16	0.208
Number of treated tumors (1/2/3)	30/15/2	51/11/2	0.071
Mean iodized oil dose (mL)	2.9 (0.6–8.0)	2.5 (0.6–6.0)	0.060
Initial iodized oil uptake (good/fair)	58/8	66/13	0.488

Notes: Data in brackets denote data range; no statistically significant difference was observed between the two groups for any of the parameters.

Abbreviations: AFP, α-fetoprotein; DCP, des-carboxy-prothrombin.